[HTML][HTML] Considerations for the development of iPSC-derived cell therapies: A review of key challenges by the JSRM-ISCT iPSC Committee
M Madrid, U Lakshmipathy, X Zhang, K Bharti, DM Wall… - Cytotherapy, 2024 - Elsevier
Since their first production in 2007, human induced pluripotent stem cells (iPSCs) have
provided a novel platform for the development of various cell therapies targeting a spectrum …
provided a novel platform for the development of various cell therapies targeting a spectrum …
Detection of residual pluripotent stem cells in cell therapy products utilizing droplet digital PCR: an international multisite evaluation study
S Yasuda, K Bando, MP Henry… - Stem Cells …, 2024 - academic.oup.com
The presence of residual undifferentiated pluripotent stem cells (PSCs) in PSC-derived cell
therapy products (CTPs) is a major safety issue for their clinical application, due to the …
therapy products (CTPs) is a major safety issue for their clinical application, due to the …
[HTML][HTML] Multisite studies for optimization of a highly efficient culture assay used for in vitro detection of residual undifferentiated human pluripotent stem cells …
T Watanabe, S Yasuda, S Kusakawa, T Kuroda… - Regenerative …, 2024 - Elsevier
Abstract Introduction MEASURE2 (Multisite Evaluation Study on Analytical Methods for Non-
clinical Safety Assessment of HUman-derived REgenerative Medical Products 2) is a …
clinical Safety Assessment of HUman-derived REgenerative Medical Products 2) is a …
Forging the Way: Pioneering Regeneration in Volume 19 of Regenerative Medicine
J Hagan, M Giboney - Regenerative Medicine, 2024 - Taylor & Francis
Full article: Forging the Way: Pioneering Regeneration in Volume 19 of Regenerative Medicine
Skip to Main Content Taylor and Francis Online homepage Taylor and Francis Online homepage …
Skip to Main Content Taylor and Francis Online homepage Taylor and Francis Online homepage …